Patents by Inventor PHILIP AMBERY

PHILIP AMBERY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING INFLAMMATORY DISEASES WITH A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR
    Publication number: 20240398774
    Abstract: This disclosure relates to methods for treating a chronic inflammatory disease or disorder in a subject having type 2 diabetes mellitus or being predisposed to type 2 diabetes mellitus. This disclosure also relates to methods for preventing development of diabetes mellitus due to glucocorticoid-induced hyperglycemia or inhibiting progression of preexisting type 2 diabetes mellitus in a subject.
    Type: Application
    Filed: September 16, 2022
    Publication date: December 5, 2024
    Inventors: Mary N BROWN, Philip AMBERY, Christina KEEN
  • COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF PROTEINURIA CHRONIC KIDNEY DISEASE
    Publication number: 20240307383
    Abstract: Methods for treating high proteinuria chronic kidney disease and/or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose combination of zibotentan and dapagliflozin are disclosed.
    Type: Application
    Filed: February 7, 2024
    Publication date: September 19, 2024
    Inventors: Philip Ambery, Peter Greasley, Anne-Kristina Mercier, Mikael Sunnåker
  • COMBINATION THERAPIES FOR TREATMENT OF CIRRHOSIS WITH PORTAL HYPERTENSION
    Publication number: 20240058331
    Abstract: A method of treating liver cirrhosis in a subject in need thereof. The method includes administering to the subject a composition. The composition includes a therapeutically effective amount of zibotentan and dapagliflozin.
    Type: Application
    Filed: August 11, 2023
    Publication date: February 22, 2024
    Inventors: Philip AMBERY, Peter GREASLEY
  • DAPAGLIFLOZIN AND AMBRISENTAN FOR THE PREVENTION AND TREATMENT OF COVID-19
    Publication number: 20230165856
    Abstract: The present disclosure is directed to the use of dapagliflozin and ambrisentan for the treatment and prevention of coronavirus disease 2019 (COVID-19), SARS-CoV-2 infection, and/or symptoms thereof.
    Type: Application
    Filed: April 28, 2021
    Publication date: June 1, 2023
    Inventors: Philip AMBERY, Peter GREASLEY, Sven MOOSMANG, Magnus ALTHAGE
  • COMBINATION THERAPY USING GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20230012936
    Abstract: Provided herein are methods of improving glycemic control, reducing weight, and/or treating type 2 diabetes mellitus in human patients comprising administering GLP-1/glucagon agonist peptides, dapagliflozin, and metformin.
    Type: Application
    Filed: December 1, 2020
    Publication date: January 19, 2023
    Inventors: ARMANDO FLOR, PHILIP AMBERY
  • GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20220041681
    Abstract: Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonist peptides.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 10, 2022
    Inventors: MARIA ALEKSANDRA BEDNAREK, LUTZ ULRICH JERMUTUS, PHILIP AMBERY, MARCELLA PETRONE
  • GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20200354426
    Abstract: Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonist peptides.
    Type: Application
    Filed: April 22, 2020
    Publication date: November 12, 2020
    Inventors: MARIA ALEKSANDRA BEDNAREK, LUTZ ULRICH JERMUTUS, PHILIP AMBERY, MARCELLA PETRONE
  • Glucagon and GLP-1 co-agonists for the treatment of obesity
    Patent number: 10676517
    Abstract: Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonists peptides.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 9, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Maria Aleksandra Bednarek, Lutz Ulrich Jermutus, Philip Ambery, Marcella Petrone
  • GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20190185537
    Abstract: Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonists peptides.
    Type: Application
    Filed: March 10, 2017
    Publication date: June 20, 2019
    Inventors: MARIA ALEKSANDRA BEDNAREK, LUTZ ULRICH JERMUTUS, PHILIP AMBERY, MARCELLA PETRONE